CMKLR1

Source: Wikipedia, the free encyclopedia.
CMKLR1
Identifiers
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl
UniProt
RefSeq (mRNA)

NM_004072
NM_001142343
NM_001142344
NM_001142345

NM_008153
NM_001359060

RefSeq (protein)

NP_001135815
NP_001135816
NP_001135817
NP_004063

NP_032179
NP_001345989

Location (UCSC)Chr 12: 108.29 – 108.34 MbChr 5: 113.75 – 113.79 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Chemokine like receptor 1 also known as ChemR23 (Chemerin Receptor 23) is a

Specialized proresolving mediators#EPA-derived resolvins (i.e. RvE)).[8] The murine receptor that shares almost 80% homology with the human receptor, is called Dez.[9]

Tissue distribution

CMKLR1 shows wide RNA expression profile but is notably high in plasmacytoid dendritic cells, macrophages, cardiomyocytes, adipocytes and endothelial cells.[10]

Function

Activating CMKLR1 by an agonist mobilizes intracellular calcium and causes the activation of several other signaling cascades like the ERK1 and NF-κB. Initial studies of CMKLR1 suggested that it might have a role in the inflammatory pathways. Its cognate ligand, chemerin was found in joint aspirate from rheumatoid arthritis and absent in aspirate from degenerative arthritis. CMKLR1 expression by plasmacytoid dendritic cells and macrophages also helped foster this idea. In vitro chemotaxis assays showed it to be utilized in attracting these cells. As an adipokine receptor it has a role in adipogenesis and adipocyte maturation.[11] It seems also to have a role in peripheral insulin resistance.[12]

Also studies using the mouse

chemerin peptides showed that these peptides suppressed and helped resolve the peritonitis in mice.[13] The same model showed that this particular molecule enhances macrophage efferocytosis (phagocyting apoptotic cells).[14]

Receptor antagonist CCX832

CCX832 is an

antagonises the effect of CMKLR1.[15][16][17] It is listed on the Guide to Pharmacology database as the only example of a CMKLR1 antagonist. Its chemical structure is undisclosed.[18]

The substance was originally developed for use as a pharmaceutical drug against

GlaxoSmithKline (GSK).[19] Development was terminated after a Phase I clinical trial in 2012.[20]

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000174600Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000042190Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ "Entrez Gene: CMKLR1 chemokine-like receptor 1".
  6. PMID 8976386
    .
  7. .
  8. .
  9. .
  10. .
  11. .
  12. .
  13. .
  14. .
  15. .
  16. .
  17. .
  18. ^ "Chemerin receptor – IUPHAR/BPS Guide to Pharmacology". www.guidetopharmacology.org. Retrieved 7 April 2017.
  19. ^ "ChemoCentryx Identifies Novel Small Molecule ChemR23 Antagonist for the Treatment of Inflammatory Diseases". ChemoCentryx. 2010-04-10. Archived from the original on 2011-05-19. Retrieved 2017-04-14.
  20. ^ "ChemoCentryx, GSK discontinue ChemR23 antagonist". BioCentury. 7 February 2012.

External links

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This page is based on the copyrighted Wikipedia article: CMKLR1. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy